Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Virtual Booth

Contact Supplier

Jai Radhe Sales is your partner for all your sourcing needs.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

$ API Reference Price

$ API Reference Price

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 499,120

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

4DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 101-00-8, Triisopropanolamine cyclic borate, Triisopropanolamine borate, Borester 21, Boric acid, tris(1-amino-2-propyl) ester, Nsc15099

Molecular Formula

C₉H₁₈BNO₃

Molecular Weight

199.06 g/mol

InChI Key

IWKGJTDSJPLUCE-UHFFFAOYSA-N

1 2D Structure

CT-001

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

3,7,10-trimethyl-2,8,9-trioxa-5-aza-1-borabicyclo[3.3.3]undecane

2.1.2 InChI

InChI=1S/C9H18BNO3/c1-7-4-11-5-8(2)13-10(12-7)14-9(3)6-11/h7-9H,4-6H2,1-3H3

2.1.3 InChI Key

IWKGJTDSJPLUCE-UHFFFAOYSA-N

2.1.4 Canonical SMILES

B12OC(CN(CC(O1)C)CC(O2)C)C

2.2 Synonyms

2.2.1 Depositor-Supplied Synonyms

1. 101-00-8

2. Triisopropanolamine Cyclic Borate

3. Triisopropanolamine Borate

4. Borester 21

5. Boric Acid, Tris(1-amino-2-propyl) Ester

6. Nsc15099

7. Triisopropanolamine Cyclic Borate;borester 21; Nsc 15099

8. 2,8,9-trioxa-5-aza-1-borabicyclo(3.3.3)undecane, 3,7,10-trimethyl-

9. 2,8,9-trioxa-5-aza-1-borabicyclo[3.3.3]undecane, 3,7,10-trimethyl-

10. Nsc 15099

11. Ai3-61110

12. 2-propanol, 1,1',1''-nitrilotri-, Cyclic Borate

13. Mfcd03791298

14. 2-propanol, 1,1',1''-nitrilotri-, Borate

15. Dtxsid50905879

16. 3,7,10-trimethyl-4,6,11-trioxa-1-aza-5-borabicyclo[3.3.3]undecane

17. Nsc-15099

18. Wln: Z1y1&oboy1z1&oy1z1

19. Akos006229267

20. 2-propanol, 1,1',1''-nitrilotri-, Cyclic Ester With Boric Acid (h3bo3) (1:1)

21. 2-propanol, 1,1',1''-nitrilotri-, Cyclic Ester With Boric Acid (h3bo3) (1:1) (van)

22. As-72042

23. Db-058548

24. Cs-0015223

25. Ft-0645346

26. T2943

27. 2-propanol,1',1''-nitrilotri-, Cyclic Borate

28. D92646

29. A897267

30. J-200318

31. 2,9-trioxa-5-aza-1-borabicyclo[3.3.3]undecane, 3,7,10-trimethyl-

32. 2-propanol,1',1''-nitrilotri-, Cyclic Ester With Boric Acid (h3bo3) (1:1)

33. 27664-53-5

2.3 Create Date

2005-03-26

3 Chemical and Physical Properties

Molecular Formula	C₉H₁₈BNO₃
Molecular Weight	199.06 g/mol
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	0
Exact Mass	199.1379736 g/mol
Monoisotopic Mass	199.1379736 g/mol
Topological Polar Surface Area	30.9 Å²
Heavy Atom Count	14
Formal Charge	0
Complexity	171
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	3
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Find CT-001 manufacturers, exporters & distributors on PharmaCompass

CT-001

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

$ API Reference Price

DEVELOPMENTS

4 Drugs in Development

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 499,120

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

4DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?